← Return to all publications

Articles using B-355

2019

1. 1. O. Timmermand, J. Elgqvist, K. Beattie, A. Örbom, E. Larsson, S. Eriksson, D. Thorek, B. Beattie, T. Tran, D. Ulmert, S. Strand. Preclinical efficacy of hK2 targeted [¹⁷⁷Lu]hu11B6 for prostate cancer theranostics

      Theranostics, vol. 9, 2019, pp. 2129-2142

   2. A. A. Liu Kanan, T. Radon, S. Shah, M. Weeks, J. J. Foster Sosabowski, L. Dumartin, T. Crnogorac-Jurcevic. AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting

      Oncotarget, vol. 10, 2019, pp. 4276-4289

2018

1. 1. E. Deshayes, R. Ladjohounlou, P. Le Fur, A. Pichard, C. Lozza, V. Boudousq, S. Sevestre, M. Jarlier, R. Kashani, J. J. Koch J. Sosabowski Foster, N. Chouin, F. Bruchertseifer, A. Morgenstern, P. Kotzki, I. Navarro-Teulon, J. Pouget. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer

      J Nucl Med, vol. 59, 2018, pp. 1234-1242

   2. M. Autenrieth, C. Seidl, F. Bruchertseifer, T. Horn, F. Kurtz, B. Feuerecker, C. C. D'Alessandria Pfob, S. Nekolla, C. Apostolidis, S. Mirzadeh, J. Gschwend, M. Schwaiger, K. Scheidhauer, A. Morgenstern. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study

      Eur J Nucl Med Mol Imaging, vol. 45, 2018, pp. 1364-1371